Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | J. Finley |
Contact Details
Address: 7750 El Camino Real, Suite 2A Carlsbad, California 92009 United States | |
| Phone | 858 704 4900 |
| Website | palisadebio.com |
Stock Details
| Ticker Symbol | PALI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001357459 |
| CUSIP Number | 696389105 |
| ISIN Number | US6963894026 |
| Employer ID | 52-2007292 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | Chief Operating Officer and Chief Medical Officer |
| Dr. Joerg Heyer Ph.D. | Head of Translational Science and Medicine |
| Ryker Willie | Senior Vice President of Finance and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 8, 2025 | SCHEDULE 13G | Filing |
| Oct 8, 2025 | SCHEDULE 13G | Filing |
| Oct 8, 2025 | SCHEDULE 13G | Filing |
| Oct 7, 2025 | SCHEDULE 13G | Filing |
| Oct 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 2, 2025 | 424B4 | Prospectus |
| Oct 1, 2025 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Sep 30, 2025 | EFFECT | Notice of Effectiveness |
| Sep 29, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 26, 2025 | 8-K | Current Report |